Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

US Patent 10792360 · Granted Oct 6, 2020

Estimated economic value: $280,385,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of treating focal segmental glomerulosclerosis2025
Methods of treating solid tumors with CCR2 antagonists2024
Compositions and methods for treating inflammatory bowel disease using CCR9 inhi2024
Compositions and methods for treating inflammatory bowel disease using CCR9 inhi2024
Methods of treating hidradenitis suppurativa2023
Reducing tumor burden by administering CCR1 antagonists in combination with PD-12023
Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or2023
CXCR7 inhibitors for the treatment of cancer2022
Treatment of focal segmental glomerulosclerosis with CCR2 antagonists2022
Method of Treating Focal Segmental Glomerulosclerosis2022
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD2022
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD2022